Helus Pharma Inc.
HELP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001833141
In the last 90 days, Helus Pharma Inc. insiders filed 8 open-market purchases and 0 sales; 99 institutions reported holding it in 13F filings for Q2 2026, worth $197.6M in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $8.42M in total
- 8
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +19 vs. previous quarter
- 99
- 13F valueReported value at the end of Q2 2026
- $197.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in CAD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- CAD -113.1M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.66M
- Shares sold short
- Change
- −345.7K
- −11.5% vs. previous
- Days to cover
- 2.05
- At average daily volume
Superinvestors holding HELP, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding HELP at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Helus Pharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 (view filing)8:13 PM ET | Sep 29 | 2 days | Cavers GregChief Financial Officer | PPurchase | +3.00K | $12.91 | +$38.7K | New position3.00K after | |
| Sep 21, 2026 (view filing)5:07 PM ET | Sep 21 | Same day | Halstead MichaelChief Executive Officer | PPurchase | +100.0K | $13.47 | +$1.35M | +145.8%168.6K after | |
| Sep 11, 2026 (view filing)9:04 AM ET | Sep 8 | 3 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $12.47 | +$1.25M | +2.4%4.27M after | Duplicate filing |
| Sep 11, 2026 (view filing)9:03 AM ET | Sep 8 | 3 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $12.47 | +$1.25M | +2.4%4.27M after | |
| Sep 11, 2026 (view filing)9:01 AM ET | Sep 8 | 3 daysLate | So Eric H. L.Executive Chair | PPurchase | +100.0K | $12.39 | +$1.24M | +2.3%4.47M after | |
| Sep 10, 2026 (view filing)6:21 AM ET | Sep 4 | 6 daysLate | So Eric H. L.Executive Chair | PPurchase | +100.0K | $12.09 | +$1.21M | +2.3%4.37M after | |
| Sep 10, 2026 (view filing)6:19 AM ET | Sep 3 | 7 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $11.78 | +$1.18M | +2.5%4.17M after | |
| Sep 9, 2026 (view filing)5:47 PM ET | Sep 1 | 8 daysLate | So Eric H. L.Executive Chair | PPurchase | +95.0K | $11.81 | +$1.12M | +2.3%4.27M after | |
| Sep 9, 2026 (view filing)11:03 AM ET | Aug 31 | 9 daysLate | Glavine PaulChief Growth Officer | PPurchase | +90.0K | $11.59 | +$1.04M | +2.3%4.07M after |
Top 10 13F holders, Q2 2026
See all 99 holdersThe largest institutional positions in Helus Pharma Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 3,851,654 | $25.5M | 0.77% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,271,400 | $21.6M | 0.41% | −561,443−14.6% | Reduced |
| Adage Capital Partners GP, L.L.C. | 3,060,000 | $20.2M | 0.03% | +2,360,000+337.1% | Added |
| Millennium Management LLC | 2,632,156 | $17.4M | 0.01% | +216,315+9.0% | Added |
| Rosalind Advisors, Inc. | 1,956,814 | $12.9M | 4.86% | +425,000+27.7% | Added |
| Sphera Funds Management Ltd. | 1,620,753 | $10.7M | 1.53% | +633,663+64.2% | Added |
| Acorn Capital Advisors, LLC | 1,540,266 | $10.2M | 2.78% | 00.0% | Unchanged |
| DCF Advisers, LLC | 1,434,988 | $9.49M | 2.48% | +743,000+107.4% | Added |
| Sio Capital Management, LLC | 1,300,000 | $8.59M | 1.47% | +1,300,000 | New |
| Nan Fung Group Holdings Ltd | 987,222 | $6.53M | 4.96% | +527,222+114.6% | Added |
Holders of 5% or more of HELP
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Helus Pharma Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 13G | 9.90%5.11M shares | New | Nov 7, 20251 filing | Nov 7, 2025 | SEC |
| Adage Capital Management, L.P. | 13G/A | 7.48%5.48M shares | +2.19 ppfrom 5.29% | Aug 12, 20262 filings | Nov 12, 2026 | SEC |
| So Eric H. L. | 13D | 5.80%4.42M shares | New | Sep 9, 20261 filing | Sep 9, 2026 | SEC |
| Glavine Paul | 13D | 5.80%4.41M shares | New | Sep 9, 20261 filing | Sep 9, 2026 | SEC |
| Millennium Management LLC | 13G/A | 5.70%2.83M shares | +0.70 ppfrom 5.00% | Mar 26, 20263 filings | Apr 22, 2026 | SEC |